TABLE 1.

Time to viral suppression among adults and adolescents with HIV infection diagnosed in 2010 and 2011, 14 U.S. jurisdictions

				Months from diagnosis to first suppressed viral loada
					≤12	≤24
Characteristic	Linkage to care	No.	%	Mean	%	%	p-valueb
Total	Within 1 month	16,801	64.6	15.4	64.9	76.1
	Within 2–3 months	3,771	14.5	18.1	58.2	72.7	<.0001
	Within 3 months	20,572	79	15.9	63.6	75.5	NA
	Not linked to care	5,454	21	34.0	17.0	32.7	NA
Sex
Male	Within 1 month	13,261	64.1	15.6	64.6	75.9
	Within 2–3 months	2,980	14.4	18.4	56.9	72.3	<.0001
	Within 3 months	16,241	78.6	16.1	63.2	75.2	NA
	Not linked to care	4,433	21.4	33.5	16.4	32.8	NA
Female	Within 1 month	3,540	66.1	14.8	65.8	77.1
	Within 2–3 months	791	14.8	16.1	63.0	73.9	<.0001
	Within 3 months	4,331	80.9	15.2	65.3	76.6	NA
	Not linked to care	1,021	19.1	34.1	19.5	32.2	NA
Race/ethnicity
Black/African American	Within 1 month	7,432	60.8	17.6	58.9	71
	Within 2–3 months	1,809	14.8	19.2	54.4	68.3	<.0001
	Within 3 months	9,241	75.6	18	58	70.5	NA
	Not linked to care	2,976	24.4	34.7	16.1	30.9	NA
Hispanic/Latino	Within 1 month	3,797	66.5	14.1	69.1	79.1
	Within 2–3 months	783	13.7	15.9	63.8	77.3	<.0001
	Within 3 months	4,580	80.2	14.5	68.2	78.8	NA
	Not linked to care	1,134	19.8	32.8	16.6	31.3	NA
White	Within 1 month	4,497	68.9	13.4	69.5	81.2
	Within 2–3 months	959	14.7	16.7	60.7	77	<.0001
	Within 3 months	5,456	83.6	14	68	80.4	NA
	Not linked to care	1,068	16.4	31.4	19.5	37.8	NA
Age at diagnosis
13–24	Within 1 month	3,219	56.8	18.2	57	70.1
	Within 2–3 months	966	17	20.2	51	67.1	<.0001
	Within 3 months	4,185	73.8	18.7	55.6	69.4	NA
	Not linked to care	1,484	26.2	33.7	15.6	32.5	NA
25–34	Within 1 month	4,620	62.1	16.2	62.9	74.6
	Within 2–3 months	1,151	15.5	18.3	57.3	72.3	<.0001
	Within 3 months	5,771	77.6	16.6	61.8	74.1	NA
	Not linked to care	1,670	22.4	33.4	15.5	31.1	NA
35–44	Within 1 month	3,987	67.8	14.5	67.7	78.4
	Within 2–3 months	804	13.7	15.9	62	75.7	<.0001
	Within 3 months	4,791	81.5	14.9	66.8	78	NA
	Not linked to care	1,089	18.5	34	16.9	31.8	NA
45–54	Within 1 month	3,359	70.1	13.5	69.7	79.8
	Within 2–3 months	611	12.8	16.1	63.1	76.6	<.0001
	Within 3 months	3,970	82.9	14	68.6	79.3	NA
	Not linked to care	821	17.1	31.1	19.7	36.7	NA
>=55	Within 1 month	1,616	72	13.3	70.1	80.1
	Within 2–3 months	239	10.6	13.6	67.2	77.6	<.001
	Within 3 months	1,855	82.6	13.6	69.7	79.8	NA
	Not linked to care	390	17.4	32.7	25	34.1	NA
Transmission category
Male-to-male sexual contact	Within 1 month	9,119	65.2	15.1	65.7	77.2
	Within 2–3 months	2,143	15.3	18	57	72.6	<.0001
	Within 3 months	11,262	80.5	15.7	64	76.3	NA
	Not linked to care	2,734	19.5	32.2	17.4	36.2	NA
Injection drug use	Within 1 month	692	63.4	17.5	60	70.4
	Within 2–3 months	140	12.8	16.8	61.3	73.9	0.228
	Within 3 months	832	76.3	17.5	60.2	71	NA
	Not linked to care	259	23.7	33.4	16	29.9	NA
Male-to-male sexual contact and injection drug use	Within 1 month	444	63.9	16.3	60.4	74.1
	Within 2–3 months	130	18.7	18.8	51.1	75.8	<.01
	Within 3 months	574	82.6	17	58.3	74.5	NA
	Not linked to care	121	17.4	31.2	19.1	37.8	NA
Heterosexual contact	Within 1 month	2,428	65.9	14.4	66.1	78
	Within 2–3 months	600	16.3	17.1	59.1	72.7	<.0001
	Within 3 months	3,028	82.2	15	64.7	77	NA
	Not linked to care	655	17.8	31.5	20.2	37.2	NA

N = 26,026

^aSuppressed viral load defined as ≤200 copies/mL.

^bWilcoxon test of equality over strata 1 months vs. 2–3 months.